Dopamine Uptake Inhibitors
"Dopamine Uptake Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake.
| Descriptor ID |
D018765
|
| MeSH Number(s) |
D27.505.519.562.437.220 D27.505.519.625.150.800 D27.505.519.625.600.220 D27.505.696.577.150.800 D27.505.696.577.600.220
|
| Concept/Terms |
Dopamine Uptake Inhibitors- Dopamine Uptake Inhibitors
- Reuptake Inhibitors, Dopamine
- Inhibitors, Dopamine Uptake
- Uptake Inhibitors, Dopamine
- Inhibitors, Dopamine Reuptake
- Dopamine Reuptake Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Dopamine Uptake Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Dopamine Uptake Inhibitors".
This graph shows the total number of publications written about "Dopamine Uptake Inhibitors" by people in this website by year, and whether "Dopamine Uptake Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2002 | 1 | 0 | 1 |
| 2003 | 4 | 0 | 4 |
| 2005 | 1 | 0 | 1 |
| 2006 | 3 | 0 | 3 |
| 2007 | 2 | 1 | 3 |
| 2008 | 3 | 0 | 3 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 0 | 1 | 1 |
| 2013 | 1 | 2 | 3 |
| 2014 | 3 | 0 | 3 |
| 2015 | 1 | 2 | 3 |
| 2016 | 2 | 0 | 2 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Dopamine Uptake Inhibitors" by people in Profiles.
-
Rivastigmine does not alter cocaine-induced subjective effects or self-administration. Pharmacol Biochem Behav. 2019 10; 185:172758.
-
FAAH variant Pro129Thr modulates subjective effects produced by cocaine administration. Am J Addict. 2018 10; 27(7):567-573.
-
eIF2a-mediated translational control regulates the persistence of cocaine-induced LTP in midbrain dopamine neurons. Elife. 2016 12 13; 5.
-
Estradiol Facilitation of Cocaine Self-Administration in Female Rats Requires Activation of mGluR5. eNeuro. 2016 Sep-Oct; 3(5).
-
Comparison of Diabetes Risk Following Smoking Cessation Treatment Using Varenicline Versus Bupropion Among Obese Smokers. Subst Use Misuse. 2015; 50(13):1628-37.
-
Genomic predictors of remission to antidepressant treatment in geriatric depression using genome-wide expression analyses: a pilot study. Int J Geriatr Psychiatry. 2016 May; 31(5):510-7.
-
Safety and Preliminary Efficacy of the Acetylcholinesterase Inhibitor Huperzine A as a Treatment for Cocaine Use Disorder. Int J Neuropsychopharmacol. 2015 Sep 12; 19(3):pyv098.
-
Evaluation and neuroimaging of the Horner syndrome. Can J Ophthalmol. 2015 Apr; 50(2):107-11.
-
Attenuation of cocaine-induced locomotor activity in male and female mice by active immunization. Am J Addict. 2014 Nov-Dec; 23(6):604-7.
-
Direct regulation of diurnal Drd3 expression and cocaine reward by NPAS2. Biol Psychiatry. 2015 Mar 01; 77(5):425-433.